The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
Allergan Aesthetics, an AbbVie company, has received Health Canada approval for Boey (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients.
Boey is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines.
“Health Canada’s approval of Boey marks an important scientific and regulatory milestone in advancing toxin science. As the world’s first approval of a botulinum neurotoxin based on serotype E in aesthetics, Boey represents a meaningful advancement in aesthetic medicine—a fast-acting neurotoxin with a differentiated profile that expands the treatment options for clinicians and patients,” says Roopal Thakkar, MD, executive vice president of research and development and chief scientific officer at AbbVie, in a release.
A new Allergan Aesthetics survey found that 80% of people are open to learning about new treatments to get the results they want, and 79% wish they could temporarily preview the outcome of an aesthetic treatment. Despite growing interest in facial injectables, many patients are hesitant to take the next step due to uncertainty around treatment outcomes and committing to long-lasting results, according to a press release from Allergan Aesthetics.
“With its truly differentiated profile, Boey is redefining aesthetics and expanding what’s possible by giving practitioners another option to tailor treatment to individual needs and goals, specifically, the ability to try a toxin without the long-term commitment,” says Nicole Mowad-Nassar, senior vice president, AbbVie, and president, global Allergan Aesthetics, in a release “Allergan Aesthetics is proud to bring this innovation to Canada first and to continue advancing options that help shape the future of aesthetic medicine.”
Allergan Aesthetics plans to begin training healthcare professionals on the appropriate use of Boey and is preparing for a commercial launch in the upcoming months as trenibotulinumtoxinE is under review for approval in multiple other countries.
ID 412749530 © Anatolii Rabizo | Dreamstime.com
